Advanced Medical Optics, Inc. (AMO), a global leader in ophthalmic surgical devices and eye care products, today reconfirmed its 2006 and 2007 revenue guidance and increased its 2006 and 2007 adjusted earnings-per-share guidance to reflect the impacts of the $450 million convertible senior subordinated note offering (plus up to an additional $50 million of notes subject to the initial purchasers option) purchase of $500 million worth of its common stock and intent to purchase up to $100 million of aggregate principal amount of its outstanding convertible notes.
Finanzen.net
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Kleresca Approved in EU for Dermatological Platform
The treatment does not damage the skin’s natural barriers.
Pro-Kratom Nonprofit Pushes Back on Deaths FDA Attributed to Substance
The FDA issued warning letters in May to three U.S. distributors of more than 65 kratom products for sales of unapproved new drugs claiming effectiveness in treating opioid addiction and withdrawal.
FDAnews Device Daily Bulletin
ADVANCED MEDICAL OPTICS RECONFIRMS REVENUE GUIDANCE AND UPDATES ADJUSTED EPS
June 9, 2006